SecBot SecBot
SECBOTREPLAY Home › Report › AXSM

AXSM · Axsome announced the first patient dosed in the FOCUS-2 Phase 3 trial…

Axsome Therapeutics, Inc. · PRESS-RELEASE filed Jul 7, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Jul 7, 2026 at 07:00 ET

Axsome announced the first patient dosed in the FOCUS-2 Phase 3 trial of solriamfetol for children with ADHD, a 468-patient placebo-controlled study. This is a pipeline-progression event that extends the solriamfetol ADHD program into a younger pediatric population, but no efficacy data or commercial timelines were provided. The event is positive for the pipeline narrative but lacks financial impact or near-term catalyst.

  • First patient dosed in FOCUS-2 Phase 3 trial evaluating solriamfetol for children aged 6 to <12 with ADHD
  • Trial is randomized, double-blind, placebo-controlled; ~468 patients randomized 1:1:1 to one of two solriamfetol doses or placebo for 6 weeks
  • Primary endpoint: change from baseline to week 6 on ADHD-RS-5 total score
  • Previously Axsome initiated FOCUS-3 Phase 3 trial of solriamfetol in adolescents (12 to <18) with ADHD

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access